Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells

[1]  G. Vasanthakumar,et al.  Uptake and metabolism of daunorubicin by human myelocytic cells , 2004, Cancer Chemotherapy and Pharmacology.

[2]  N. Nissen,et al.  Cross resistance and cellular uptake of 4′-O-methyldoxorubicin in experimental tumors with acquired resistance to doxorubicin , 2004, Cancer Chemotherapy and Pharmacology.

[3]  G. Vasanthakumar,et al.  Comparative uptake, retention and cytotoxicity of daunorubicin by human myeloid cells. , 1986, Biochemical pharmacology.

[4]  N. K. Ahmed.  Daunorubicin reductase activity in human normal lymphocytes, myeloblasts and leukemic cell lines. , 1985, European journal of cancer & clinical oncology.

[5]  D. Kessel,et al.  Daunorubicin accumulation by human myeloblasts varying in anthracycline resistance. , 1984, Cancer letters.

[6]  S. Yanovich,et al.  Effects of verapamil on daunomycin cellular retention and cytotoxicity in P388 leukemic cells. , 1984, Cancer research.

[7]  J. Stadler,et al.  Correlation of unstable multidrug cross resistance in Chinese hamster ovary cells with a homogeneously staining region on chromosome 1 , 1983, Molecular and cellular biology.

[8]  R. Ganapathi,et al.  Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. , 1983, Cancer research.

[9]  R. Giavazzi,et al.  Isolation and preliminary characterization of an Adriamycin-resistant murine fibrosarcoma cell line. , 1983, Cancer research.

[10]  B. Spengler,et al.  Drug resistance in Chinese hamster lung and mouse tumor cells. , 1983, Cancer treatment reports.

[11]  T. Tsuruo,et al.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. , 1982, Cancer research.

[12]  R. Rosenberg,et al.  Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[13]  N. Tanaka,et al.  Evidence of altered influx of adriamycin into anthracycline-resistant cells. , 1981, The Journal of antibiotics.

[14]  P. Thayer,et al.  Comparative uptake, metabolism and retention of anthracyclines by tumors growing in vitro and in vivo. , 1980, European journal of cancer.

[15]  M. Inaba,et al.  Enhanced efflux of actinomycin D, vincristine, and vinblastine in adriamycin-resistant subline of P388 leukemia. , 1979, Cancer letters.

[16]  R. Johnson,et al.  Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. , 1979, Cancer research.

[17]  N. K. Ahmed,et al.  Comparison and characterization of mammalian xenobiotic ketone reductases. , 1979, The Journal of pharmacology and experimental therapeutics.

[18]  A. Gola.  Daunorubicin reductase activity in leukemia leukocyte homogenates. , 1979, Archivum immunologiae et therapiae experimentalis.

[19]  Johnson Rk,et al.  In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. , 1978 .

[20]  T. Skovsgaard.  Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. , 1978, Cancer research.

[21]  R. Johnson,et al.  Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia. , 1978, Biochemical pharmacology.

[22]  N. K. Ahmed,et al.  Heterogeneity of anthracycline antibiotic carbonyl reductases in mammalian livers. , 1978, Biochemical pharmacology.

[23]  Wang Jj,et al.  Uptake of adriamycin and daunomycin in L1210 and human leukemia cells: a comparative study. , 1976 .

[24]  D. Chervinsky,et al.  Uptake of adriamycin and daunomycin in L1210 and human leukemia cells: a comparative study. , 1976, Journal of medicine.

[25]  V. Ling.  Drug resistance and membrane alteration in mutants of mammalian cells. , 1975, Canadian journal of genetics and cytology. Journal canadien de genetique et de cytologie.

[26]  V. Ling,et al.  Reduced permeability in CHO cells as a mechanism of resistance to colchicine , 1974, Journal of cellular physiology.

[27]  K. Danø.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. , 1973, Biochimica et biophysica acta.

[28]  M. Boiron,et al.  Daunorubicin in the therapy of acute granulocytic leukemia. , 1973, Cancer research.

[29]  R. Benjamin,et al.  High‐dose daunorubicin therapy for acute nonlymphocytic leukemia: Correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity , 1972, Cancer.

[30]  K. Danø.  Cross resistance between vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo. , 1972, Cancer chemotherapy reports.

[31]  K. Danø.  Development of resistance to adriamycin (NSC-123127) in Ehrlich ascites tumor in vivo. , 1972, Cancer chemotherapy reports.

[32]  K. Danø.  Development of resistance to daunomycin (NSC-82151) in Ehrlich ascites tumor. , 1971, Cancer chemotherapy reports.

[33]  J. L. Biedler,et al.  Cellular resistance to daunomycin in Chinese hamster cells in vitro. , 1971, Cancer research.

[34]  N. Bachur,et al.  Daunomycin metabolism in rat tissue slices. , 1970, The Journal of pharmacology and experimental therapeutics.

[35]  A. Moore,et al.  Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods. , 1970, Cancer chemotherapy reports.